GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huaren Pharmaceutical Co Ltd (SZSE:300110) » Definitions » Piotroski F-Score

Huaren Pharmaceutical Co (SZSE:300110) Piotroski F-Score : 7 (As of Jun. 04, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Huaren Pharmaceutical Co Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Huaren Pharmaceutical Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Huaren Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

SZSE:300110' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 9
Current: 7

During the past 13 years, the highest Piotroski F-Score of Huaren Pharmaceutical Co was 9. The lowest was 3. And the median was 6.


Huaren Pharmaceutical Co Piotroski F-Score Historical Data

The historical data trend for Huaren Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huaren Pharmaceutical Co Piotroski F-Score Chart

Huaren Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 4.00 3.00 5.00 6.00

Huaren Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 7.00 6.00 7.00

Competitive Comparison of Huaren Pharmaceutical Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Huaren Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Huaren Pharmaceutical Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Huaren Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Huaren Pharmaceutical Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 41.179 + 54.802 + 50.979 + 50.823 = ¥198 Mil.
Cash Flow from Operations was 58.652 + 71.408 + 108.539 + 110.517 = ¥349 Mil.
Revenue was 425.804 + 386.881 + 420.329 + 406.703 = ¥1,640 Mil.
Gross Profit was 181.61 + 183.404 + 166.029 + 170.978 = ¥702 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(5138.159 + 5316.716 + 5171.841 + 5165.697 + 5001.385) / 5 = ¥5158.7596 Mil.
Total Assets at the begining of this year (Mar23) was ¥5,138 Mil.
Long-Term Debt & Capital Lease Obligation was ¥606 Mil.
Total Current Assets was ¥2,635 Mil.
Total Current Liabilities was ¥1,531 Mil.
Net Income was 49.062 + 49.11 + 57.568 + 41.103 = ¥197 Mil.

Revenue was 336.472 + 382.429 + 515.106 + 403.242 = ¥1,637 Mil.
Gross Profit was 137.676 + 164.904 + 208.803 + 168.011 = ¥679 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(5342.88 + 5315.74 + 5114.551 + 5162.819 + 5138.159) / 5 = ¥5214.8298 Mil.
Total Assets at the begining of last year (Mar22) was ¥5,343 Mil.
Long-Term Debt & Capital Lease Obligation was ¥505 Mil.
Total Current Assets was ¥2,749 Mil.
Total Current Liabilities was ¥1,813 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Huaren Pharmaceutical Co's current Net Income (TTM) was 198. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Huaren Pharmaceutical Co's current Cash Flow from Operations (TTM) was 349. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=197.783/5138.159
=0.03849297

ROA (Last Year)=Net Income/Total Assets (Mar22)
=196.843/5342.88
=0.03684212

Huaren Pharmaceutical Co's return on assets of this year was 0.03849297. Huaren Pharmaceutical Co's return on assets of last year was 0.03684212. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Huaren Pharmaceutical Co's current Net Income (TTM) was 198. Huaren Pharmaceutical Co's current Cash Flow from Operations (TTM) was 349. ==> 349 > 198 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=606.004/5158.7596
=0.11747087

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=504.798/5214.8298
=0.09680047

Huaren Pharmaceutical Co's gearing of this year was 0.11747087. Huaren Pharmaceutical Co's gearing of last year was 0.09680047. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=2634.865/1530.911
=1.7211092

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=2748.997/1812.931
=1.51632743

Huaren Pharmaceutical Co's current ratio of this year was 1.7211092. Huaren Pharmaceutical Co's current ratio of last year was 1.51632743. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Huaren Pharmaceutical Co's number of shares in issue this year was 1181.928. Huaren Pharmaceutical Co's number of shares in issue last year was 1181.117. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=702.021/1639.717
=0.42813546

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=679.394/1637.249
=0.41496071

Huaren Pharmaceutical Co's gross margin of this year was 0.42813546. Huaren Pharmaceutical Co's gross margin of last year was 0.41496071. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=1639.717/5138.159
=0.31912539

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=1637.249/5342.88
=0.30643567

Huaren Pharmaceutical Co's asset turnover of this year was 0.31912539. Huaren Pharmaceutical Co's asset turnover of last year was 0.30643567. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+1+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Huaren Pharmaceutical Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Huaren Pharmaceutical Co  (SZSE:300110) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Huaren Pharmaceutical Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Huaren Pharmaceutical Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Huaren Pharmaceutical Co (SZSE:300110) Business Description

Traded in Other Exchanges
N/A
Address
No. 187 Zhuzhou Road, Qingdao, Shandong, CHN, 266100
Huaren Pharmaceutical Co Ltd is a China-based company engaged in the manufacture, and sale of non-polyvinyl chloride and Non-PVC large capacity preparations. Its categories of products include conventional infusion, therapy infusion, and nutrition infusion. The company distributes its products in domestic market, with Northeast China as its main market.
Executives
Yang Xiao Dong Director
Bo Guo Xiu Executives
Zhou Xi Jian Director
Mao Yu Wei Supervisors
Chu Xiao Jun Executives
Zhou Qiang Directors, executives
Ji Sheng Bin Executives
Xiao Wei Wen Executives
Shen Hong Ce Executives
Li Xiao Li Executives
Liu Qian Executives
Wang Wen Ping Executives
Liang Fu You Director
Liang Fu Dong Director
Gong Ling Secretary Dong

Huaren Pharmaceutical Co (SZSE:300110) Headlines

No Headlines